Keywords
Last Name
Institution

George Raptis

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address
    Other Positions
    TitleASSOCIATE PROFESSOR
    InstitutionMount Sinai
    DepartmentObstetrics, Gynecology and Reproductive Science


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013 Oct; 141(3):429-35.
      View in: PubMed
    2. Mouzaki A, Panagoulias I, Raptis G, Farri-Kostopoulou E. Cord blood leptin levels of healthy neonates are associated with IFN-? production by cord blood T-cells. PLoS One. 2012; 7(7):e40830.
      View in: PubMed
    3. Bleiweiss IJ, Raptis G. Look again: the importance of second opinions in breast pathology. J Clin Oncol. 2012 Jun 20; 30(18):2175-6.
      View in: PubMed
    4. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011 Oct; 90(4):605-11.
      View in: PubMed
    5. Adelson K, Germain D, Raptis G, Biran N. Hormonal modulation in the treatment of breast cancer. Endocrinol Metab Clin North Am. 2011 Sep; 40(3):519-32, viii.
      View in: PubMed
    6. Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal Chem. 2010 Dec 15; 82(24):10186-93.
      View in: PubMed
    7. Barginear MF, Raptis G. Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer. Expert Rev Anticancer Ther. 2010 Feb; 10(2):149-51.
      View in: PubMed
    8. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, Rohan T, Sparano J, Raptis G, Castaldi M, Estabrook A, Feldman S, Weltz C, Kemeny M. Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. J Oncol. 2009; 2009:871250.
      View in: PubMed
    9. Higgins SC, Montgomery GH, Raptis G, Bovbjerg DH. Effect of pretreatment distress on daily fatigue after chemotherapy for breast cancer. J Oncol Pract. 2008 Mar; 4(2):59-63.
      View in: PubMed
    10. Bleiweiss IJ, Raptis G. Translation, please. Lancet Oncol. 2007 Dec; 8(12):1044-5.
      View in: PubMed
    11. Crew KD, Capodice JL, Greenlee H, Apollo A, Jacobson JS, Raptis G, Blozie K, Sierra A, Hershman DL. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. J Cancer Surviv. 2007 Dec; 1(4):283-91.
      View in: PubMed
    12. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007 Nov; 107(2):310-5.
      View in: PubMed
    13. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007 Sep 1; 25(25):3877-83.
      View in: PubMed
    14. Metafratzi ZM, Georgiadis AN, Ioannidou CV, Alamanos Y, Vassiliou MP, Zikou AK, Raptis G, Drosos AA, Efremidis SC. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007 Sep-Oct; 36(5):338-44.
      View in: PubMed
    15. Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, Hershman DL. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol. 2007 Mar 20; 25(9):1089-98.
      View in: PubMed
    16. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B, Richter CE, Braumann UD, Einenkel J. Pattern of invasion is of prognostic value in surgically treated cervical cancer patients. Gynecol Oncol. 2006 Dec; 103(3):906-11.
      View in: PubMed
    17. Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA, Fleming TP. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6528-35.
      View in: PubMed
    18. Horn LC, Raptis G, Fischer U, Hentschel B, Köhler U, Richter CE, Martin R. CD44-v6 concentrations in carcinoma of the uterine cervix: lack of prognostic significance. Arch Gynecol Obstet. 2005 Dec; 273(2):104-6.
      View in: PubMed
    19. Bovbjerg DH, Montgomery GH, Raptis G. Evidence for classically conditioned fatigue responses in patients receiving chemotherapy treatment for breast cancer. J Behav Med. 2005 Jun; 28(3):231-7.
      View in: PubMed
    20. Horn LC, Pippig S, Raptis G, Fischer U, Köhler U, Hentschel B, Martin R. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z J Obstet Gynaecol. 2002 Oct; 42(4):383-6.
      View in: PubMed
    21. Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs. 2002 Sep; 13(8):791-5.
      View in: PubMed
    22. Fischer U, Raptis G, Gessner W, Roschlau U, Dressel K, Bilek K, Horn LC. [Epidemiology and pathogenesis of cervical cancer]. Zentralbl Gynakol. 2001 Apr; 123(4):198-205.
      View in: PubMed
    23. Horn LC, Fischer U, Hänel C, Kuhn H, Raptis G, Bilek K. p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread. Pathol Res Pract. 2001; 197(9):605-9.
      View in: PubMed
    24. Donnelly JM, Kornblith AB, Fleishman S, Zuckerman E, Raptis G, Hudis CA, Hamilton N, Payne D, Massie MJ, Norton L, Holland JC. A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. Psychooncology. 2000 Jan-Feb; 9(1):44-56.
      View in: PubMed
    25. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. J Clin Oncol. 1999 Apr; 17(4):1118.
      View in: PubMed
    26. D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 1999 Feb; 5(2):275-9.
      View in: PubMed
    27. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol. 1999 Jan; 17(1):93-100.
      View in: PubMed
    28. Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L. Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest. 1998; 16(2):67-71.
      View in: PubMed
    29. Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. Phase II study of semisynthetic paclitaxel in metastatic breast cancer. Eur J Cancer. 1997 Nov; 33(13):2198-202.
      View in: PubMed
    30. Seidman AD, Hudis CA, Raptis G, Baselga J, Fennelly D, Norton L. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology (Williston Park). 1997 Mar; 11(3 Suppl 2):20-8.
      View in: PubMed
    31. Kritz AD, Raptis G, Menendez-Botet C, Maslak P, Jakubowski A. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am J Hematol. 1996 Feb; 51(2):117-21.
      View in: PubMed
    32. Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol. 1996 Feb; 23(1 Suppl 1):58-64.
      View in: PubMed
    33. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Jan; 14(1):58-65.
      View in: PubMed
    34. Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol. 1995 Dec; 22(6 Suppl 15):18-23.
      View in: PubMed
    35. Crown J, Raptis G, Hamilton N, Hudis C, Vahclat L, Fennelly D, Norton L. High-dose chemotherapy of breast cancer. Can J Oncol. 1995 Dec; 5 Suppl 1:80-2.
      View in: PubMed
    36. Vahdat L, Raptis G, Fennelly D, Hamilton N, Reich L, Tiersten A, Harrison M, Hudis C, Moore M, Yao TJ, et al. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res. 1995 Nov; 1(11):1267-73.
      View in: PubMed
    37. Seidman AD, Hudis CA, Fennelly D, Raptis G, Baselga J, Norton L. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):108-16.
      View in: PubMed
    38. Crown J, Hamilton N, Raptis G, Kritz A, Vahdat L, Norton L. Carboplatin and etoposide in metastatic breast cancer. Ann Oncol. 1995 Apr; 6(4):403.
      View in: PubMed
    39. Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L. High-dose chemotherapy of breast cancer: current status and developmental strategies. Eur J Cancer. 1995; 31A(5):809-11.
      View in: PubMed
    40. Vahdat L, Raptis G, Fennelly D, Crown J. High-dose chemotherapy of metastatic breast cancer: a review. Cancer Invest. 1995; 13(5):505-10.
      View in: PubMed
    41. Shapiro F, Yao TJ, Raptis G, Reich L, Norton L, Moore MA. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood. 1994 Nov 15; 84(10):3567-74.
      View in: PubMed
    42. Fennelly D, Vahdat L, Schneider J, Reich L, Hamilton N, Hakes T, Raptis G, Wasserheit C, Kritz A, Gulati S, et al. High-intensity chemotherapy with peripheral blood progenitor cell support. Semin Oncol. 1994 Apr; 21(2 Suppl 2):21-5; quiz 26, 58.
      View in: PubMed
    43. Kane MA, Roth E, Raptis G, Schreiber C, Waxman S. Effect of intracellular folate concentration on the modulation of 5-fluorouracil cytotoxicity by the elevation of phosphoribosylpyrophosphate in cultured human KB cells. Cancer Res. 1987 Dec 15; 47(24 Pt 1):6444-50.
      View in: PubMed
    Raptis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067